Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 11Lymphoma, Large-Cell, Anaplastic 8Neoplasm Metastasis 7Multiple Myeloma 6Lymphoma 6Neoplasms 5Colorectal Neoplasms 4Adenocarcinoma 4Uveal Melanoma 3Neuroblastoma 3Melanoma 3Hematologic Neoplasms 3Granuloma, Plasma Cell 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Glioma 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1

Interventions

pazopanib 2Ifosfamide 2Etoposide 2Carboplatin 2vandetanib 1ruxolitinib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Everolimus 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Relapsed Pediatric Solid Tumor × Crizotinib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡